Greg Ryslik, Ph.D., has joined as chief data officer, and Michael Boretti, Ph.D., has joined as chief business officer.
Ryslik is a statistician, data scientist and artificial intelligence researcher with experience building and leading data initiatives in companies ranging across the biotech, autotech, healthtech and fintech domains.
Prior to Celsius, he was vice president of data science at Mindstrong Health, a healthcare company transforming mental health treatment through measurement science and artificial intelligence.
Previously, Ryslik was the senior director and head of data science at Faraday Future, an electric vehicle startup in Los Angeles as well as a leader of the service data science group at Tesla Motors in Palo Alto.
Earlier in his career, he performed machine learning research and nonclinical biostatistics research at Genentech.
Concurrently, Ryslik holds an adjunct assistant professor position at Pennsylvania State University and has lectured on statistics for artificial intelligence, machine learning at Stanford University Continuing Studies.
Boretti brings to Celsius Therapeutics nearly 15 years of experience in the biotechnology industry, including leadership roles encompassing business development, strategic planning, and program and alliance management.
He has a strong track record of planning, negotiating and implementing strategic alliances across a wide range of collaboration structures.
He joins Celsius from Epizyme, where he was vice president of business development and responsible for the formation new partnerships, including key collaborations with Boehringer Ingelheim and Roche, while also overseeing management of numerous other strategic alliances.
Prior to Epizyme, Dr. Boretti worked in roles of increasing responsibility at Aveo Oncology, most recently serving as vice president, corporate development and alliance management, where he drove the formation of partnerships around many of Aveo's clinical- and discovery-stage programs, including significant transactions with Novartis, Janssen and Astellas.
Prior to Aveo, Dr. Boretti was a consultant in the life sciences practice at L.E.K. Consulting, a global strategic consulting firm.
He holds an undergraduate degree in engineering science from the University of Virginia and a Ph.D. in bioengineering from the University of Pennsylvania.
Celsius Therapeutics is charting a new course of target and drug discovery by applying a systematic approach to single-cell sequencing of patient tissue, combining massive datasets, complex algorithms, and machine learning to discover first-in-class precision therapies with a transformative impact on the lives of patients with autoimmune diseases and cancer.
Celsius was launched in 2018, is backed by Third Rock Ventures and GV (formerly Google Ventures), and is based in Cambridge, Mass.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial